Impact of a multifaceted intervention on physicians' knowledge, attitudes and practices in relation to pharmaceutical incentivisation: protocol for a randomised control trial.
Impact of a multifaceted intervention on physicians' knowledge, attitudes and practices in relation to pharmaceutical incentivisation: protocol for a randomised control trial.
复制标题
DOI：
10.1136/bmjopen-2022-067233
复制
发表时间：
2022-11-04
期刊：
影响因子：
2.9
通讯作者：
中科院分区：
文献类型：
--
作者：
在私营部门占卫生系统较大部分的情况下，牟利可能会凌驾于病人的福祉之上。在与制药公司的互动中，私人全科医生（GP）可能会遇到利益冲突（COI），这种情况下，GP的专业决策的公正性可能会受到次要利益的影响，例如处方特定药品品牌的经济收益。本研究是一项随机对照试验，旨在评估多方面干预对全科医生医疗实践的影响。研究样本包括419名注册的全科医生，他们拥有/在私人诊所工作，并将被随机分配到干预组和对照组。干预组的全科医生将接触到关于医学伦理的情感和教育研讨会，而对照组的全科医生将获得关于一般医学主题的研讨会。主要结果指标将是全科医生的处方实践，而次要结果指标将是他们对药物激励引起的COI的知识和态度。除了一种新的标准化的医药代表（SPSR）的方法，其中现场研究人员将模拟与GP，调查前和调查后的药品营销，和定性访谈将进行收集数据的GP的知识，态度和做法的COI与药品激励措施。将进行单变量和多变量统计分析，以衡量全科医生的知识，态度和做法的变化，而定性分析将增加我们对定量SPSR数据的理解。已获得巴基斯坦国家生物伦理委员会（# 4-87/NBC-582/21/1364）、阿加汗大学（# 2020-4759-1129）和伦敦卫生和热带医学院（# 26506）的伦理批准。我们将在研究完成后的6-9个月内公布结果。ISRCTN12294839。
In settings where the private sector constitutes a larger part of the health system, profit-gathering can take primacy over patients’ well-being. In their interactions with pharmaceutical companies, private general practitioners (GPs) can experience the conflict of interest (COI), a situation whereby the impartiality of GPs’ professional decision making may be influenced by secondary interests such as financial gains from prescribing specific pharmaceutical brands. This study is a randomised controlled trial to assess the impact of a multifaceted intervention on GPs’ medical practice. The study sample consists of 419 registered GPs who own/work in private clinics and will be randomly assigned to intervention and control groups. The intervention group GPs will be exposed to emotive and educational seminars on medical ethics, whereas control group GPs will be given seminars on general medical topics. The primary outcome measure will be GPs’ prescribing practices, whereas the secondary outcome measures will be their knowledge and attitudes regarding COI that arises from pharmaceutical incentivisation. In addition to a novel standardised pharmaceutical representatives (SPSR) method, in which field researchers will simulate pharmaceutical marketing with GPs, presurvey and postsurvey, and qualitative interviewing will be performed to collect data on GPs’ knowledge, attitudes and practices in relation to COI linked with pharmaceutical incentives. Univariate and multivariate statistical analyses will be performed to measure a change in GPs’ knowledge, attitudes and practices, while qualitative analysis will add to our understanding of the quantitative SPSR data. Ethics approval has been obtained from the Pakistan National Bioethics Committee (# 4-87/NBC-582/21/1364), the Aga Khan University (# 2020-4759-1129) and the London School of Hygiene and Tropical Medicine (# 26506). We will release results within 6–9 months of the study’s completion. ISRCTN12294839.
登录
查看更多内容
影响因子：
--
作者：
Sismondo S
通讯作者：
Sismondo S
影响因子：
2.8
作者：
Khazzaka, Micheline
通讯作者：
Khazzaka, Micheline
影响因子：
2.4
作者：
Saleem, Hummera;Shabbir, Malik Shahzad;Khan, Bilal
通讯作者：
Khan, Bilal
影响因子：
3.2
作者：
Khan, Mishal S.;Durrance-Bagale, Anna;Hanefeld, Johanna
通讯作者：
Hanefeld, Johanna
影响因子：
2.7
作者：
Siddiqui, Usman Tariq;Shakoor, Amarah;Farid-Ul-Husnain, Syed
通讯作者：
Farid-Ul-Husnain, Syed